Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

NCT04535401 2024-10-10

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Phase 1 Unknown

10 enrolled

Gastrointestinal

Stomach Neoplasms, Colorectal Neoplasms

NCT04095273 2024-04-02

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

Phase 1 Completed

56 enrolled

Ataxia Telangiectasia, Hereditary Sensory and Autonomic Neuropathies

NCT04267939 2023-12-21

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

Phase 1 Terminated

14 enrolled

Gynecologic

Ovarian Neoplasms

NCT03188965 2023-10-11

First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

Phase 1 Completed

229 enrolled

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT05010096 2022-05-27

BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Tumor-Agnostic

Neoplasm Metastasis